New variants of inducible Cre recombinase: a novel mutant of Cre-PR fusion protein exhibits enhanced sensitivity and an expanded range of inducibility.

We have developed a novel inducible Cre mutant with enhanced recombinase activity to mediate genetic switching events. The protein, designated Cre*PR, is composed of a new Cre mutant at the N-terminus followed by the ligand-binding domain (LBD) of the progesterone receptor (PR). The response to low doses of inducer is significantly enhanced by elongating the C-terminus of the PR LBD from amino acid 891 to 914. The mutant Cre lacks the first 18 amino acids and contains a Val-->Ala substitution at position 336, thereby destroying a cryptic splice donor at the 3'-end of CRE: The latter mutation reduces unwanted background recombinase activity in the absence of the synthetic ligand RU486 by a factor of at least 10 to an almost undetectable level. Thus, the recombinase activity turns out to be inducible by a factor of >200. We expect Cre*PR to serve as a valuable tool for conditional expression of genes both in vitro and in vivo.

[1]  M. Gartenberg,et al.  Controlling gene expression in yeast by inducible site-specific recombination. , 2000, Nucleic acids research.

[2]  J. Vassalli,et al.  Inducible and irreversible control of gene expression using a single transgene. , 2000, Nucleic acids research.

[3]  P. Chambon,et al.  Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis , 2000, Nature.

[4]  D. Metzger,et al.  Temporally controlled somatic mutagenesis in smooth muscle , 2000, Genesis.

[5]  M. T. Hasan,et al.  Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P Chambon,et al.  Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. , 1999, Nucleic acids research.

[7]  J. Gorski,et al.  Efficient bicistronic expression of cre in mammalian cells. , 1999, Nucleic acids research.

[8]  E. Casanova,et al.  Inducible site-specific recombination in the brain. , 1999, Journal of molecular biology.

[9]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[10]  R Kuhn,et al.  Temporally and spatially regulated somatic mutagenesis in mice. , 1998, Nucleic acids research.

[11]  F. Guo,et al.  Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse , 1997, Nature.

[12]  Y. Wang,et al.  Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator , 1997, Gene Therapy.

[13]  P Chambon,et al.  Ligand-activated site-specific recombination in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Angrand,et al.  Regulation of Cre recombinase activity by the synthetic steroid RU 486. , 1996, Nucleic acids research.

[15]  F. Sablitzky,et al.  Inducible site-directed recombination in mouse embryonic stem cells. , 1996, Nucleic acids research.

[16]  M Aguet,et al.  Inducible gene targeting in mice , 1995, Science.

[17]  C. Logie,et al.  Ligand-regulated site-specific recombination. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. O’Malley,et al.  The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor , 1992, Cell.

[19]  R. Jaenisch,et al.  A generic intron increases gene expression in transgenic mice , 1991, Molecular and cellular biology.